CELU רווחיות גולמית celularity.com

Celularity Inc. is a biotech startup whose stability relies on external investments due to a lack of sales. The annual gross margin demonstrates operational dynamics where -17.00 is the current level of the indicator. Patents for placental cells and a complex technological process provide business protection. Stringent FDA requirements for factory certification create an insurmountable barrier for new market entrants.
פילוחים אנליטיים ודוחות נתונים של חברת Celularity Corp (CELU)

For Celularity Inc. (CELU), limited pricing power resulting from rigid US insurance tariffs directly impacts the efficiency of cell therapy production. This gross margin level reflects the portion of revenue remaining after direct costs, demonstrating the fundamental margin of safety and the business's ability to cover operating expenses, which allows investors to assess the model's resilience to fiscal pressures.